• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $TEM

    Tempus AI Inc.

    Subscribe to $TEM
    $TEM
    Computer Software: Programming Data Processing
    Technology

    IPO Year: 2024

    Exchange: NASDAQ

    Recent Analyst Ratings for Tempus AI Inc.

    DatePrice TargetRatingAnalyst
    4/21/2025$60.00Buy
    BTIG Research
    2/25/2025$50.00 → $55.00Overweight → Neutral
    Analyst
    2/12/2025Outperform → Mkt Perform
    William Blair
    2/5/2025$58.00 → $74.00Buy
    TD Cowen
    12/13/2024$60.00Outperform
    Wolfe Research
    12/9/2024$74.00Buy
    Guggenheim
    11/11/2024$45.00 → $65.00Buy → Hold
    Stifel
    10/2/2024$45.00 → $60.00Buy → Neutral
    BofA Securities
    8/12/2024$40.00Neutral
    Piper Sandler
    7/9/2024$41.00Buy
    BofA Securities
    See more ratings

    Tempus AI Inc. SEC Filings

    See more
    • SEC Form 144 filed by Tempus AI Inc.

      144 - Tempus AI, Inc. (0001717115) (Subject)

      5/9/25 4:18:56 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Amendment: SEC Form SCHEDULE 13G/A filed by Tempus AI Inc.

      SCHEDULE 13G/A - Tempus AI, Inc. (0001717115) (Subject)

      5/9/25 4:14:44 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • SEC Form 424B3 filed by Tempus AI Inc.

      424B3 - Tempus AI, Inc. (0001717115) (Filer)

      5/6/25 4:12:24 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • SEC Form 10-Q filed by Tempus AI Inc.

      10-Q - Tempus AI, Inc. (0001717115) (Filer)

      5/6/25 4:07:27 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Tempus AI Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Tempus AI, Inc. (0001717115) (Filer)

      5/6/25 4:02:12 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • SEC Form SCHEDULE 13G filed by Tempus AI Inc.

      SCHEDULE 13G - Tempus AI, Inc. (0001717115) (Subject)

      4/30/25 7:18:29 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • SEC Form 424B3 filed by Tempus AI Inc.

      424B3 - Tempus AI, Inc. (0001717115) (Filer)

      4/23/25 8:12:02 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • SEC Form 8-K filed by Tempus AI Inc.

      8-K - Tempus AI, Inc. (0001717115) (Filer)

      4/23/25 8:09:27 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • SEC Form DEFA14A filed by Tempus AI Inc.

      DEFA14A - Tempus AI, Inc. (0001717115) (Filer)

      4/7/25 4:08:29 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • SEC Form DEF 14A filed by Tempus AI Inc.

      DEF 14A - Tempus AI, Inc. (0001717115) (Filer)

      4/7/25 4:06:13 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology

    Tempus AI Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on Tempus AI with a new price target

      BTIG Research initiated coverage of Tempus AI with a rating of Buy and set a new price target of $60.00

      4/21/25 8:39:11 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Tempus AI downgraded by Analyst with a new price target

      Analyst downgraded Tempus AI from Overweight to Neutral and set a new price target of $55.00 from $50.00 previously

      2/25/25 7:14:46 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Tempus AI downgraded by William Blair

      William Blair downgraded Tempus AI from Outperform to Mkt Perform

      2/12/25 7:11:34 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • TD Cowen resumed coverage on Tempus AI with a new price target

      TD Cowen resumed coverage of Tempus AI with a rating of Buy and set a new price target of $74.00 from $58.00 previously

      2/5/25 8:03:48 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Wolfe Research initiated coverage on Tempus AI with a new price target

      Wolfe Research initiated coverage of Tempus AI with a rating of Outperform and set a new price target of $60.00

      12/13/24 8:31:40 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Guggenheim initiated coverage on Tempus AI with a new price target

      Guggenheim initiated coverage of Tempus AI with a rating of Buy and set a new price target of $74.00

      12/9/24 8:35:27 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Tempus AI downgraded by Stifel with a new price target

      Stifel downgraded Tempus AI from Buy to Hold and set a new price target of $65.00 from $45.00 previously

      11/11/24 7:48:55 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Tempus AI downgraded by BofA Securities with a new price target

      BofA Securities downgraded Tempus AI from Buy to Neutral and set a new price target of $60.00 from $45.00 previously

      10/2/24 7:59:05 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Piper Sandler initiated coverage on Tempus AI with a new price target

      Piper Sandler initiated coverage of Tempus AI with a rating of Neutral and set a new price target of $40.00

      8/12/24 8:04:47 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • BofA Securities initiated coverage on Tempus AI with a new price target

      BofA Securities initiated coverage of Tempus AI with a rating of Buy and set a new price target of $41.00

      7/9/24 9:34:20 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology

    Tempus AI Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tempus Reports First Quarter 2025 Results

      Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2025. Revenue increased 75.4% year-over-year to $255.7 million in the first quarter of 2025 Quarterly gross profit increased 99.8% year-over-year, reaching $155.2 million with continued gross margin improvement in both Genomics and Data and services Announced multi-year, strategic collaborations with AstraZeneca and Pathos to work together to build the largest multimodal foundation model in oncology, resulting in additional $200.0 million in data licensing and model development fees over the next

      5/6/25 4:01:00 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • AI Healthcare Boom Gains Speed as Regulators and Innovators Align

      Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, May 5, 2025 /PRNewswire/ --The integration of artificial intelligence (AI) into healthcare is here to stay, and adoption is accelerating. According to research from PYMNTS Intelligence which polled C-suite executives at healthcare companies generating at least $1 billion in annual revenue, 90% already see positive ROI from investments in generative AI (GenAI). Analysts are projecting that by 2035 the gross value added by AI to the healthcare industry will be $461 billion on top of a baseline $2.26 trillion. Behind the scenes, several new AI healthcare tech developments are taking place, with updates rec

      5/5/25 12:35:00 PM ET
      $GEHC
      $SDGR
      $TEM
      $TVGN
      Medical Electronics
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Computer Software: Programming Data Processing
    • Tempus Announces Notetaker, its AI-Powered Clinical Assistant for Psychiatry

      Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the launch of Notetaker, an AI-powered clinical assistant to aid psychiatrists in generating progress notes. Notetaker, which is available in Tempus Hub, ambiently records patient sessions to generate transcripts and clinical notes that can be seamlessly stored in patients' electronic health records. Notetaker complements Tempus' existing mental health platform designed to support clinicians in delivering personalized care. It joins other precision medicine solutions, including the Tempus nP pharmacogenomic test and PRO™, the company's patient reported

      5/5/25 8:30:00 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Tempus TIME Network Expands Support of Phase I Clinical Trials To Accelerate Activation and Enrollment

      The TIME Precision Network is a newly-formed group of investigators across TIME's provider site network dedicated to supporting Phase I trials Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, is leveraging its TIME Network to expand its support in phase I clinical trials. Since its inception in 2019, TIME has supported the rapid patient identification and site activation of clinical trials, bringing cutting-edge trials to patients in communities across the U.S. To further expand its support of phase I trials, Tempus has formed the TIME Precision Network, a group of investigators leading the phase I study platform

      5/1/25 8:30:00 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Tempus Publishes Study Validating the Benefits of xF+, its Comprehensive Liquid Biopsy Assay for Therapy Selection

      The validation study recently published in the Journal of Molecular Diagnostics Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, "Analytical Validation of NGS-based Comprehensive Liquid Biopsy Assay for Therapy" in the Journal of Molecular Diagnostics. Data from this study supports the utility of xF+ as a non-invasive technique to detect actionable variants including resistance mutations, identify clinically relevant biomarkers, and monitor disease progression. The xF+ assay integrates with the Tempus multimodal database, supporting therapeutic recommendations and clinica

      4/29/25 8:30:00 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Tempus Introduces Loop, an AI-Powered Target Discovery and Validation Platform

      The new, proprietary target discovery platform integrates RWD, human biological modeling, and CRISPR screens to accelerate novel target identification Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced Tempus Loop, a new oncology-focused platform for target discovery and validation. Loop is Tempus' proprietary approach to novel target identification that integrates real-world patient data (RWD) with human-derived biological models and CRISPR-screens, all leveraging AI to rapidly uncover insights for pre-clinical therapeutic development. One of the biggest industry challenges has been translating pro

      4/28/25 8:30:00 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Tempus Announces 18 Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025

      Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that 18 abstracts, including one oral presentation, have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, on April 25 - 30 in Chicago. Tempus researchers will showcase scientific and clinical research that highlight the transformative impact of AI on oncology treatment and patient outcomes. "Tempus is proud to showcase a comprehensive collection of scientific research this year, highlighting the impact of our multimodal dataset and AI-enabled diagnostic solutions on cancer research," said Kate

      4/25/25 8:30:00 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Tempus to Report First Quarter 2025 Financial Results on May 6

      Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the first quarter of 2025 on Tuesday, May 6, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 4680302 Domestic Dial-in Number: (800) 715-9871 International Dial-in Number: (646) 307

      4/24/25 8:30:00 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology

      Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced multi-year, strategic collaborations with AstraZeneca (NASDAQ:AZN) and Pathos AI, Inc., in which the companies will work together to build a multimodal foundation model in oncology which can be used to gather biological and clinical insights, discover novel drug targets, and develop therapeutics for the broader oncology community. Tempus' de-identified oncology data will be used to build the foundation model. Upon completion, the model will be shared among all three parties to advance their individual efforts to improve patient care. The agreements i

      4/23/25 8:00:00 AM ET
      $AZN
      $TEM
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Computer Software: Programming Data Processing
      Technology
    • Tempus Unveils Advisory Board Featuring Leading Physicians From Across the U.S.

      Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the launch of the Tempus Advisory Board. The Tempus Advisory Board is a vital resource for the company in maintaining high standards and ensuring that the strategy and offerings continue to be grounded in expert knowledge from outside the organization. This group of engaged medical professionals is providing guidance, expertise and strategic advice to Tempus on matters related to research, product development, and clinical utility across the various aspects of the company's AI-enabled platform. "Since the beginning, our belief has been that clinical

      4/18/25 8:30:00 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology

    Tempus AI Inc. Financials

    Live finance-specific insights

    See more
    • Tempus Reports First Quarter 2025 Results

      Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2025. Revenue increased 75.4% year-over-year to $255.7 million in the first quarter of 2025 Quarterly gross profit increased 99.8% year-over-year, reaching $155.2 million with continued gross margin improvement in both Genomics and Data and services Announced multi-year, strategic collaborations with AstraZeneca and Pathos to work together to build the largest multimodal foundation model in oncology, resulting in additional $200.0 million in data licensing and model development fees over the next

      5/6/25 4:01:00 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Tempus to Report First Quarter 2025 Financial Results on May 6

      Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the first quarter of 2025 on Tuesday, May 6, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 4680302 Domestic Dial-in Number: (800) 715-9871 International Dial-in Number: (646) 307

      4/24/25 8:30:00 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Tempus to Report Fourth Quarter and Full Year 2024 Financial Results on February 24

      Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2024 on Monday, February 24, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 9601821 Domestic Dial-in Number: (888) 596-4144 International Dial-i

      2/11/25 8:30:00 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Tempus to Report Third Quarter 2024 Financial Results on November 4

      Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Monday, November 4, 2024. The company will hold the third quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The company's conference call that was previously scheduled for November 7, 2024 has been canceled. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the

      11/3/24 8:06:00 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Tempus to Report Third Quarter 2024 Financial Results on November 7

      Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Thursday, November 7, 2024. The company will hold the third quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 7177136 Domestic Dial-in Number: (800) 715-9871 International Dial-in

      10/24/24 8:30:00 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Tempus to Report Second Quarter 2024 Financial Results on August 6

      Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the second quarter on Tuesday, August 6, 2024. The company will hold the second quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 6326328 Domestic Dial-in Number: (800) 715-9871 International Dial-in

      7/17/24 9:30:00 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology

    Tempus AI Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Tempus Ai, Inc. exercised 9,218,800 in-the-money shares at a strike of $2.00 and bought $17,745,000 worth of shares (3,500,000 units at $5.07) (SEC Form 4)

      4 - Tempus AI, Inc. (0001717115) (Reporting)

      8/20/24 4:17:55 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology

    Tempus AI Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Tempus AI Inc.

      SC 13G - Tempus AI, Inc. (0001717115) (Subject)

      11/12/24 5:00:02 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • SEC Form SC 13G filed by Tempus AI Inc.

      SC 13G - Tempus AI, Inc. (0001717115) (Subject)

      11/12/24 4:30:28 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Amendment: SEC Form SC 13D/A filed by Tempus AI Inc.

      SC 13D/A - Tempus AI, Inc. (0001717115) (Filed by)

      8/20/24 4:27:51 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • SEC Form SC 13G filed by Tempus AI Inc.

      SC 13G - Tempus AI, Inc. (0001717115) (Subject)

      8/8/24 4:38:12 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • SEC Form SC 13D filed by Tempus AI Inc.

      SC 13D - Tempus AI, Inc. (0001717115) (Filed by)

      7/3/24 1:05:04 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology

    Tempus AI Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Fukushima Ryan sold $1,047,239 worth of shares (20,000 units at $52.36), decreasing direct ownership by 2% to 884,460 units (SEC Form 4)

      4 - Tempus AI, Inc. (0001717115) (Issuer)

      5/8/25 4:30:06 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Director Epstein David R sold $19,795 worth of shares (370 units at $53.50), decreasing direct ownership by 1% to 25,914 units (SEC Form 4)

      4 - Tempus AI, Inc. (0001717115) (Issuer)

      5/5/25 4:15:22 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Chief Financial Officer Rogers James William was granted 4,372 shares, increasing direct ownership by 3% to 169,122 units (SEC Form 4)

      4 - Tempus AI, Inc. (0001717115) (Issuer)

      5/2/25 6:45:12 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • EVP and General Counsel Polovin Andrew was granted 5,334 shares, increasing direct ownership by 4% to 156,429 units (SEC Form 4)

      4 - Tempus AI, Inc. (0001717115) (Issuer)

      5/2/25 6:45:10 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • EVP & Chief Admin & Legal Off Phelps Erik was granted 5,334 shares, increasing direct ownership by 4% to 157,511 units (SEC Form 4)

      4 - Tempus AI, Inc. (0001717115) (Issuer)

      5/2/25 6:45:07 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Chief Accounting Officer Bartolucci Ryan M was granted 9,372 shares, increasing direct ownership by 21% to 53,872 units (SEC Form 4)

      4 - Tempus AI, Inc. (0001717115) (Issuer)

      5/2/25 6:45:05 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Director Gottlieb Scott sold $1,314,154 worth of shares (27,837 units at $47.21), decreasing direct ownership by 46% to 32,839 units (SEC Form 4)

      4 - Tempus AI, Inc. (0001717115) (Issuer)

      4/3/25 5:30:04 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Director Doudna Jennifer A sold $30,075 worth of shares (625 units at $48.12), decreasing direct ownership by 2% to 25,740 units (SEC Form 4)

      4 - Tempus AI, Inc. (0001717115) (Issuer)

      4/3/25 4:15:27 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Chief Operating Officer Fukushima Ryan sold $944,085 worth of shares (20,000 units at $47.20), decreasing direct ownership by 2% to 904,460 units (SEC Form 4)

      4 - Tempus AI, Inc. (0001717115) (Issuer)

      4/3/25 4:15:22 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Director Frederick Wayne A.I. sold $136,620 worth of shares (3,000 units at $45.54), decreasing direct ownership by 10% to 26,514 units (SEC Form 4)

      4 - Tempus AI, Inc. (0001717115) (Issuer)

      4/2/25 6:13:04 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology